Anti-KRAS Polyclonal Antibody

Catalog No.

PHB91101

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human KRAS (Met1-Arg149).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

c-Ki-ras,RASK2,GTPase KRas,K-Ras 2,c-K-ras,KRAS,Ki-Ras,KRAS2

Purification

Purified by antigen affinity column.

Accession

P01116

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial., PMID:40512191

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report., PMID:40488279

Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730

First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report., PMID:40460045

Macrophage activation determines muscle wasting in pancreatic cancer., PMID:40442475

Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer., PMID:40437561

Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer., PMID:40427538

Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC., PMID:40374470

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era., PMID:40361510

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival., PMID:40349418

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer., PMID:40346041

KRAS/NRAS/BRAF mutational profile and association with clinicopathological characteristics in patients with metastatic colorectal cancer., PMID:40342724

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer., PMID:40340861

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312., PMID:40304209

Mutation Mapping of PD-L1 Expression in Advanced Non-small Cell Lung Cancer: A Real-world Retrospective Cohort Study., PMID:40289990

Site-directed antibodies targeting driver mutations of the KRAS protein., PMID:40252917

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer., PMID:40246819

Pancreatic Cancer: Pathogenesis and Clinical Studies., PMID:40182139

Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells., PMID:40172967

Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580

Cetuximab and Paclitaxel Drug Response in Head and Neck Tumor Stem Cells., PMID:40149887

A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179

BRAF V600E protein detection by immunohistochemistry in metastatic colorectal cancer tissue: association with tumor characteristics and KRAS mutation., PMID:40135701

Update 2025: Management of Non‑Small-Cell Lung Cancer., PMID:40133478

An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer., PMID:40126545

Ras-MAPK pathway in patients with lupus nephritis., PMID:40102014

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations., PMID:40097366

KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients., PMID:40093249

Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer., PMID:40093186

The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment., PMID:40080361

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial., PMID:40055521

Discovery of mutations predictive of survival benefit from immunotherapy in first-line NSCLC: A retrospective machine learning study of IMpower150 liquid biopsy data., PMID:40043417

Cost-Effectiveness Analysis of SOX Plus Bevacizumab Versus SOX Plus Cetuximab for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer in Japan., PMID:40038004

Design, Production, and Optimization of Antigen-Specific Recombinant Antitumor Dimeric IgA Antibody., PMID:40029519

The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results., PMID:40009739

Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China., PMID:39984658

The interplay of cancer-associated fibroblasts and apoptotic cancer cells suppresses lung cancer cell growth through WISP-1-integrin ανβ3-STAT1 signaling pathway., PMID:39966869

YY1 as a mediator to enhance the resistance of KRAS mutant colorectal cancer cells to cetuximab., PMID:39959936

Biodistribution of 89Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through In Vivo PET Imaging., PMID:39959112

Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment., PMID:39944233

[Comparative analysis of EGFR gene mutations (exon 20) in sinonasal papillomas of inverted and oncocytic types]., PMID:39943724

Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC., PMID:39941857

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives., PMID:39941797

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model., PMID:39932765

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan., PMID:39931207

Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer., PMID:39927885

Immunolipid magnetic bead-based circulating tumor cell sorting: a novel approach for pathological staging of colorectal cancer., PMID:39927117

Burosumab Treatment in a Girl With Cutaneous Skeletal Hypophosphatemia Syndrome: 2-Year Follow-Up., PMID:39925163

Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses., PMID:39924128

[Immunorelated Stevens-Johnson syndrome/toxic epidermolysis caused by programmed death receptor 1 inhibitors: a case report]., PMID:39914838

Document Download

Anti-KRAS Polyclonal Antibody.pdf